| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD-0332991 | FIMM | pan-cancer | AAC | -0.031 | 0.9 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.0078 | 0.9 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | AC55649 | CTRPv2 | pan-cancer | AAC | 0.0062 | 0.9 |